Rapport d’analyse de la taille, de la part et des tendances du marché mondial de l’ustekinumab – Aperçu et prévisions de l’industrie jusqu’en 2031

Analyse du marché de l'ustekinumab

Le marché de l'ustekinumab connaît une croissance robuste, portée par son efficacité dans le traitement des maladies auto-immunes telles que le psoriasis, la maladie de Crohn et la colite ulcéreuse. Cet anticorps monoclonal, commercialisé sous la marque Stelara, cible les voies de l'interleukine-12 et de l'interleukine-23, offrant des avantages thérapeutiques significatifs aux patients atteints de maladies inflammatoires chroniques. Les développements récents comprennent des indications élargies et des essais cliniques en cours explorant son efficacité dans d'autres maladies, telles que la spondylarthrite ankylosante. Le marché se caractérise par une sensibilisation et des taux de diagnostic croissants des maladies auto-immunes, ce qui entraîne une demande accrue de thérapies innovantes. En outre, les progrès dans la formulation et les méthodes d'administration améliorent l'observance et les résultats des patients. Les stratégies concurrentielles, notamment les partenariats et les collaborations entre sociétés pharmaceutiques, contribuent également à la dynamique du marché. Dans l'ensemble, le marché de l'ustekinumab est sur le point de poursuivre son expansion, car les prestataires de soins de santé reconnaissent de plus en plus son potentiel à améliorer la qualité de vie des patients atteints de maladies auto-immunes complexes.

Taille du marché de l'ustekinumab

Français La taille du marché mondial de l'ustekinumab a été évaluée à 11,4 milliards USD en 2023 et devrait atteindre 18,03 milliards USD d'ici 2031, avec un TCAC de 5,90 % au cours de la période de prévision de 2024 à 2031. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Tendances du marché de l'ustekinumab

« Augmentation des taux de prévalence des maladies auto-immunes »

The ustekinumab market is evolving rapidly, fueled by increasing prevalence rates of autoimmune diseases such as psoriasis, Crohn’s disease, and ulcerative colitis. This monoclonal antibody, effective in targeting interleukin-12 and interleukin-23, is gaining popularity for its significant therapeutic benefits and favorable safety profile. Recent innovations include the development of biosimilars, providing cost-effective alternatives and increasing accessibility for patients. Another notable trend is the growing interest in combination therapies that enhance the efficacy of Ustekinumab by integrating it with other treatment modalities. In addition, advancements in patient monitoring and personalized medicine are driving tailored treatment approaches, improving patient outcomes. As healthcare providers and patients increasingly recognize the importance of managing chronic inflammatory conditions effectively, the ustekinumab market is expected to see substantial growth, positioning it as a cornerstone in the treatment of autoimmune diseases. Overall, the market is on a positive trajectory, driven by innovation and heightened awareness.

Report Scope and Ustekinumab Market Segmentation         

Ustekinumab Market Definition

Ustekinumab is a monoclonal antibody that selectively targets interleukin-12 (IL-12) and interleukin-23 (IL-23), two key cytokines involved in the inflammatory processes of autoimmune diseases. Approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis, Crohn's disease, and ulcerative colitis, Ustekinumab works by inhibiting these cytokines, thereby reducing inflammation and the immune response associated with these conditions. Administered via subcutaneous injection, it has shown significant efficacy in improving symptoms and the quality of life for patients suffering from chronic inflammatory disorders. s

Ustekinumab Market Dynamics

Drivers

• Expanded Therapeutic Indications

The increasing availability of advanced diagnostic technologies has significantly improved the detection and diagnosis of autoimmune disorders, such as Crohn's disease, psoriasis, and ulcerative colitis. Tools like advanced imaging, biomarker testing, and genetic profiling enable earlier and more accurate identification of these conditions. Simultaneously, growing awareness campaigns, both from healthcare providers and patient advocacy groups, have educated the public on the symptoms and risks of autoimmune diseases. This heightened awareness leads to earlier medical consultations and diagnoses, enabling timely treatment interventions. As a result, the demand for biologic therapies like Ustekinumab has risen, as patients are identified and treated earlier in the disease progression. This trend serves as a key market driver, fostering growth in the Ustekinumab market as more patients seek effective treatments.

•  Development of Biosimilars

The introduction of ustekinumab biosimilar is set to significantly enhance accessibility and affordability for patients suffering from autoimmune diseases. As healthcare costs continue to rise, biosimilars provide a cost-effective alternative to the original ustekinumab therapy, making it more accessible to a broader patient population. This increased affordability can lead to higher treatment adherence and improved patient outcomes, particularly in underserved communities where financial constraints often limit access to advanced therapies. Furthermore, the availability of biosimilars is likely to foster healthy competition in the market, driving prices down and encouraging further innovation among pharmaceutical companies. As healthcare systems recognize the benefits of biosimilars, the overall demand for ustekinumab and its biosimilars will likely increase, further propelling market growth and ensuring that more patients receive effective treatment for chronic inflammatory conditions.

Opportunities

• Development of Combination Therapies

Investigating ustekinumab's efficacy in combination with other therapies presents a promising market opportunity for enhancing treatment outcomes in patients with complex autoimmune conditions. Research indicates that using ustekinumab alongside conventional therapies or other biologics may lead to improved efficacy and reduced disease activity. This synergistic approach can address the multifaceted nature of autoimmune diseases, which often require a combination of therapeutic strategies for optimal management. By exploring various combination therapies, healthcare providers can offer more personalized treatment plans that cater to individual patient needs, ultimately improving quality of life. Furthermore, the potential success of these combinations may attract additional clinical interest and investment, driving innovation in the ustekinumab market and expanding its application across various therapeutic areas.

• Telemedicine Integration

The rise of telemedicine presents significant opportunities for improved patient management and monitoring in the ustekinumab market. With the increasing adoption of telehealth services, healthcare providers can offer real-time consultations, follow-ups, and support, making it easier for patients to engage with their treatment plans. This enhanced accessibility can lead to more consistent use of ustekinumab, as patients can communicate with their healthcare teams without the barriers of travel or time constraints. Furthermore, telemedicine enables healthcare providers to monitor patient progress closely, allowing for timely adjustments to treatment protocols when necessary. Improved communication and support can also boost patient adherence to prescribed therapies, ultimately leading to better health outcomes and reinforcing the role of ustekinumab as a critical component in managing autoimmune diseases.

Restraints/Challenges

• High Costs of Treatments

The high expense associated with ustekinumab therapy poses a significant challenge for many patients, particularly in regions with limited insurance coverage or high out-of-pocket costs. For individuals diagnosed with chronic autoimmune conditions such as psoriasis, Crohn's disease, or ulcerative colitis, the financial burden of Ustekinumab can be overwhelming, leading to treatment delays or discontinuation. This economic barrier affects access to the medication and  diminishes patient adherence to prescribed treatment protocols. Patients who struggle to afford their medications may be more likely to miss doses or abandon treatment altogether, which can result in a deterioration of their condition. Consequently, the high costs associated with ustekinumab therapy present a substantial challenge in ensuring equitable access and optimal treatment outcomes for patients in need.

• Underdeveloped Healthcare Infrastructures

In regions with underdeveloped healthcare infrastructures, the effective deployment of ustekinumab is often hindered by several significant challenges. Inadequate healthcare access means that patients may struggle to receive timely diagnoses and appropriate treatments, limiting their opportunities to benefit from Ustekinumab therapy. Furthermore, limited treatment options in these areas can exacerbate the problem, as patients may not have access to specialists familiar with biologics or advanced therapies. This lack of access can result in delayed treatment initiation or a complete lack of treatment for those in need. In addition, inadequate infrastructure can impact the supply chain, making it difficult for healthcare providers to obtain ustekinumab consistently. Consequently, these barriers restrict patient access to this crucial medication and  impede overall market growth in these regions.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Ustekinumab Market Scope

The market is segmented on the basis of drug class, demographic, application, dosage form, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Interleukin Inhibitors
• Others

Demographic

• Adult
• Pediatric

  Application

• Arthritis
• Colitis
• Lupus Erythematosus
• Myositis Multiplex with Palmoplantar Pustulosis
• Cirrhosis of the Liver
• Sarcoidosis
• Diabetes
• Others

Dosage Form

• Intravenous Solution
• Subcutaneous Solution

End-Users

• Clinics
• Hospitals
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Ustekinumab Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, drug class, demographic, application, dosage form, end-users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the Ustekinumab market, primarily due to the concentration of major pharmaceutical companies and a strong presence of key players in the industry. The region benefits from high disposable incomes, which enable patients to access advanced treatment options. In addition, a well-established healthcare infrastructure supports the efficient distribution and administration of Ustekinumab, further solidifying its dominance in this market.

Asia-Pacific region is projected to experience significant growth from 2024 to 2031, fueled by a surge in research and development activities aimed at enhancing treatment options. Increased government support for healthcare initiatives and innovation in this area is expected to bolster the market further. In addition, the growing demand for advanced therapies among the region's large population will contribute to the positive outlook for the Ustekinumab market in Asia-Pacific.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Ustekinumab Market Share

Le paysage concurrentiel du marché fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.

Les leaders du marché de l'ustekinumab opérant sur le marché sont :

• Fuji Pharma Co., Ltd. (Japon)
• Meiji Holdings Co., Ltd. (Japon)
• Mitsubishi Tanabe Pharma Corporation (Japon)
• STADA Arzneimittel AG (Allemagne)
• Formycon AG (Allemagne)
• NeuClone (Australie)
• Outlook Therapeutics, Inc. (États-Unis)
• BioXpress Therapeutics SA (Suisse)
• Johnson & Johnson Private Limited (États-Unis)
• Janssen Pharmaceuticals, Inc. (États-Unis)
• Apino Pharma CO., Ltd. (Japon)
• Synergia Life Sciences Pvt. Ltd. (Inde)

Derniers développements sur le marché de l'ustekinumab

• En juillet 2024, Celltrion a annoncé que Santé Canada avait approuvé sa présentation de nouveau médicament (PNM) pour Steqeyma (nom de développement CT-P43), un biosimilaire conçu pour le traitement des maladies auto-immunes. Ce biosimilaire s'inspire de Stelara et élargit les options de traitement pour les patients atteints de maladies telles que le psoriasis et la maladie de Crohn. Cette approbation représente une étape importante pour Celltrion, améliorant l'accès à des thérapies efficaces pour la gestion des maladies auto-immunes au Canada
• En juillet 2020, Fujifilm Kyowa Kirin Biologics a obtenu l'approbation au Japon pour le premier biosimilaire d'adalimumab du pays, couvrant des maladies comme le psoriasis, la spondylarthrite ankylosante et la maladie de Crohn. Cette approbation améliore l'accès aux thérapies biologiques pour les maladies inflammatoires chroniques. L'introduction de biosimilaires favorise la concurrence et l'accessibilité, stimulant indirectement la demande de produits biologiques comme l'ustekinumab
• En août 2020, Lupin Limited et Mylan ont lancé leur biosimilaire étanercept, Nepexto, après avoir reçu l'autorisation de mise sur le marché de la Commission européenne en mai 2020. Approuvé pour des maladies comme l'arthrite psoriasique et le psoriasis en plaques, Nepexto offre des options de traitement plus accessibles et plus abordables. Ce lancement renforce la concurrence sur le marché européen des produits biologiques, stimulant encore davantage la demande pour des alternatives comme l'ustekinumab

SKU-67573